Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tasigna Beats Sprycel To First-Line CML Punch

Executive Summary

Now that Novartis' Tasigna (nilotinib) has been approved by FDA for the treatment of first-line chronic myeloid leukemia, the race has officially begun for two second-generation BCR-ABL kinase inhibitors to supplant the venerable market-leader, Novartis' Gleevec (imatinib)
Advertisement

Related Content

Pfizer Bases Bosutinib U.S. Filing On One Single-Arm Phase II Trial
Pfizer Bases Bosutinib U.S. Filing On One Single-Arm Phase II Trial
Bristol's Once-daily Sprycel Faces Off Against Novartis' Tasigna After Clearance In First-line Leukemia
Bristol's Once-daily Sprycel Faces Off Against Novartis' Tasigna After Clearance In First-line Leukemia
Despite Headwinds On Glivec, Novartis Gears Up To Bring Tasigna To India
Goodbye Gleevec? Sprycel, Tasigna Vie For Front-Line CML Leadership
Goodbye Gleevec? Sprycel, Tasigna Vie For Front-Line CML Leadership
UK's NICE Says No To Two CML Drugs; Invites Cost-Sharing Schemes
Beyond Gleevec: What's Next For Novartis Oncology?

Topics

Advertisement
UsernamePublicRestriction

Register

PS052404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel